ProMIS Neurosciences reports Q2 EPS (29c) vs (13c) last year

“The team’s exceptional focus and execution in the first half of 2025 culminated in what has been an extraordinary past month for ProMIS and its key stakeholders,” said Neil Warma, Chief Executive Officer of ProMIS Neurosciences (PMN). “As of August 12, enrollment in the PRECISE-AD Phase 1b Alzheimer’s disease trial has surpassed 50% of the planned 128 patients, marking strong recruitment progress. Importantly, no cases of amyloid-related imaging abnormalities, including brain swelling or microhemorrhage, have been observed to date, and no patient dropouts have been reported, reinforcing PMN310’s potential favorable safety profile. At this stage, we remain on track to deliver 6-month blinded interim results in 2Q 2026 and final topline results in 4Q 2026.”